Canine cognitive dysfunction (CCD) is a nervous system disorder characterized by pathological changes in the brain that impair the mental functioning of dogs resulting in loss of memory, motor function, and learned behaviors. CCD is extremely disruptive to the pet/owner relationship due to changes in the dog’s behavior. These include disorientation and confusion, anxiety and restlessness, extreme irritability, decreased desire to play, disregard for training or house rules, lack of self-grooming, fecal and urinary incontinence and changes in sleep cycle. Clinical signs of CCD are found in 50% of dogs over the age of 11. By the age of 15, 70% of dogs display at least one sign. As with Alzheimer’s disease in humans, several biological molecules within the brain have been shown to contribute to age-related CDD. These molecules are ideal targets for antibody-based therapies. In a recent human study, health benefit for Alzheimer’s patient treated with a monoclonal antibody was demonstrated. CDD driving molecules are also ideal targets for our virus-like particle vaccine technology. HypoPet's vaccine HP010 is being developed for treatment of CCD. Lead optimization of the drug candidate has been completed.